Long-term Follow-up Study of BHC001 for TDT

Status Recruiting

Clinical Trial Summary

Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.

Clinical Trial Description

Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BHC001 in TDT subjects. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06314529
Study type	Observational
Source	Bioray Laboratories
Contact	Xiaochen Wang, PhD
Phone	021-64340008
Email	xcwang@brlmed.com
Status	Recruiting
Phase
Start date	December 14, 2022
Completion date	May 10, 2037

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05799118` - Study of the Role of Genetic Modifiers in Hemoglobinopathies
Completed	`NCT06153784` - Thalidomide and Hydroxyurea Combination in β-Thalassemia Patients	Phase 2/Phase 3
Completed	`NCT05132270` - Clinical Experience of Thalidomide in Thalassemic Patients	Phase 2/Phase 3
Recruiting	`NCT05736419` - A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)	Phase 2
Not yet recruiting	`NCT06298630` - Long-term Follow-up Study of BRL-101 for TDT
Recruiting	`NCT06041620` - Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells	N/A
Recruiting	`NCT03183375` - The Efficacy and Safety of HYDROXYUREA in Management of Beta Thalassemia Patients in Karachi Pakistan	Phase 2